A critical step in the turnover of yeast mRNAs is decapping. Two yeast proteins, Dcp1p and Dcp2p, are absolutely required for decapping, although their precise roles in the decapping reaction have not been established. To determine the function of both Dcp1p and Dcp2p in decapping, we purified recombinant versions of these proteins from Escherichia coli and examined their properties. These experiments demonstrate that copurification of Dcp1p and Dcp2p yields active decapping enzyme under a variety of conditions. Moreover, Dcp2p alone can have decapping activity under some biochemical conditions. This suggests that Dcp2p can be a catalytic subunit of the decapping complex, and Dcp1p may function to enhance Dcp2p activity, or as an additional active subunit. In addition, recombinant Dcp1p/Dcp2p prefers long mRNA substrates and is sensitive to inhibition by sequestration of the 5 end but not the 3 end of the substrate. This suggests that Dcp1p/Dcp2p contains an additional RNA-binding site spatially distinct from the active site. Finally, using two RNA-binding proteins that enhance decapping in vivo (Edc1p and Edc2p), we can reconstitute the activation of decapping with recombinant proteins. This indicates that the Edc1 and Edc2 proteins act directly on the decapping enzyme.
INTRODUCTION
The process of mRNA degradation is a common way to control gene expression. Multiple pathways exist in eukaryotic cells for the degradation of polyadenylated mRNAs (for review, see Beelman and Parker 1995) . A major RNA decay pathway has been described in yeast where both unstable and stable mRNAs are primarily degraded by a 5Ј → 3Ј mechanism of mRNA turnover. In this pathway, the first step is shortening of the 3Ј poly(A) tail (Muhlrad and Parker 1992; Decker and Parker 1993) . Once the mRNA has become oligo-adenylated (10-12 As), the mRNA becomes a substrate for a decapping reaction (Muhlrad et al. 1994 (Muhlrad et al. , 1995 . After decapping, the mRNA is rapidly degraded in a 5Ј → 3Ј direction by the Xrn1p exoribonuclease (Hsu and Stevens 1993) . Differential stabilities among diverse mRNAs are due to combinatorial variations in the rates of deadenylation and decapping (Muhlrad et al. 1994 (Muhlrad et al. , 1995 Cao and Parker 2001) . Alternatively, following deadenylation, mRNAs can be degraded in a 3Ј to 5Ј direction by the cytoplasmic exosome (Jacobs-Anderson and Parker 1998) and the resulting cap structure hydrolyzed by the DcpS scavenger decapping enzyme, which is encoded by the DCS1 gene in yeast (Wang and Kiledjian 2001; Liu et al. 2002) .
Decapping is a critical control point in the major decay pathway as it both precedes and permits the degradation of the mRNA body. The decapping reaction in vivo requires two interacting proteins, Dcp1p and Dcp2p (Beelman et al. 1996; Dunckley and Parker 1999) . The in vivo activity of this Dcp1p/Dcp2p enzyme is modulated in both positive and negative ways. For example, the efficiency of the decapping reaction is enhanced by the activity of the Pat1p/ Lsm1-7p complex and Dhh1p, a member of the DEAD box family of RNA helicases (Bonnerot et al. 2000; Bouveret et al. 2000; Tharun et al. 2000; Coller et al. 2001; Fischer and Weis 2002) . In addition, two small RNA-binding proteins, Edc1p and Edc2p, can act to stimulate the rate of decapping both in vivo and in vitro (Dunckley et al. 2001; Schwartz et al. 2003) . Although not absolutely required for decapping, all these proteins stimulate the decapping of both stable and unstable mRNAs, suggesting they are general activators of the decapping reaction. In contrast, proteins that are in-volved in translation initiation are general inhibitors of decapping. For example, the stability of the interaction between the cytoplasmic cap-binding complex and the mRNA cap structure influences how quickly the mRNA is decapped Parker 1999, 2000; Vilela et al. 2000; Ramirez et al. 2002) . Transcript-specific binding proteins that promote or inhibit the decapping reaction can also modulate the decapping rates of individual mRNAs. For example, Puf3p binds to the 3ЈUTR of the COX17 mRNA and enhances the rates of both deadenylation and decapping of this transcript (Olivas and Parker 2000) .
To understand the control of decapping, a mechanistic understanding of the properties and functions of the Dcp1 and Dcp2 proteins is required. Toward this end, we purified these proteins from Escherichia coli and examined their properties. These experiments demonstrated that Dcp2p alone has decapping activity under some biochemical conditions, but that activity is more robust in the presence of Dcp1p. Moreover, Dcp1p/Dcp2p prefers long mRNA substrates, suggesting that Dcp1p/Dcp2p contains an additional RNA-binding site that is distinct from the active site. Finally, the addition of recombinant purified Edc1p or Edc2p stimulates the recombinant decapping enzyme, indicating that the Edc1 and Edc2 proteins act directly on the decapping enzyme.
RESULTS

Purification of Dcp1p, Dcp2p, and Dcp1p+Dcp2p
To determine the functional roles of Dcp1p and Dcp2p, we purified the proteins individually or as a complex from E. coli. In these experiments, we used a carboxy-terminal truncated version of Dcp2p, referred to as Dcp2⌬Cp. We used this derivative of Dcp2p for two reasons. First, Dcp2⌬Cp contains the conserved region of Dcp2p and is sufficient to complement a dcp2⌬ strain (Dunckley and Parker 1999) . Second, the full-length Dcp2p is particularly prone to proteolysis and difficult to purify (Dunckley and Parker 1999; Dunckley et al. 2001) . As reported previously, we were initially unable to obtain any decapping activity from Dcp1p or Dcp2⌬Cp under standard decapping conditions when the individual proteins were purified (LaGrandeur and Parker 1998; Dunckley and Parker 1999) (Fig. 1) . We did observe a small amount of activity with Dcp2⌬Cp alone. The significance of this activity, however, was unclear as similar low levels of activity were observed with point mutations in Dcp2⌬Cp, which inactivate the enzyme in vivo (data not shown).
Coexpression of Dcp1p and Dcp2⌬Cp in E. coli yields decapping activity
To determine if the combination of Dcp1p and Dcp2⌬Cp was sufficient for producing decapping activity, we coexpressed Flag Dcp1p and His 6 Dcp2⌬Cp in E. coli and purified over an anti-Flag affinity column. The resulting purified protein fraction contains both Flag Dcp1p and His 6 Dcp2⌬Cp as shown by both analysis of a silver-stained protein gel and corresponding Western blot analysis (data not shown). The purified fractions were assayed for decapping activity by incubating the protein preparations with caplabeled MFA2 mRNA and detecting the release of m 7 GDP by thin layer chromatography. Purified fractions with Dcp1p and Dcp2⌬Cp have mRNA decapping activity (Fig.  1) . Similar results are obtained using a Ni 2+ affinity column, where both Flag Dcp1p and His 6 Dcp2⌬Cp copurify and the protein fraction has decapping activity (data not shown). It should be noted that these experiments are done in enzyme excess and are qualitative in nature. These results suggest that the combination of Dcp1p and Dcp2⌬Cp is sufficient to produce active decapping enzyme.
One caveat with the decapping assay used in Figure 1 is that m 7 GDP comigrates with inorganic phosphate (Pi) (Wang and Kiledjian 2001) . Therefore, we confirmed that the decapping reaction using recombinant enzyme was producing m 7 GDP by treating the products of the decapping reaction to nucleotide diphosphate kinase (NDPK). This converts m 7 GDP, but not Pi, to m 7 GTP, which has a unique migration in the TLC solvent. The product generated by the decapping reaction using the recombinant decapping enzymes is converted to m 7 GTP by treatment with NDPK, therefore indicating that the recombinant decapping enzyme is producing the expected reaction product, m 7 GDP (data not shown). In summary, these experiments demonstrated that coexpression of Dcp1p and Dcp2⌬Cp was suf- ficient for producing active recombinant decapping enzyme. To verify that the decapping activity we observed was the same as the actual decapping activity from yeast, we examined the protein requirements for decapping. Dcp2p contains a Nudix, or MutT, motif that is required for decapping in yeast (Dunckley and Parker 1999) . Thus, we determined if the Q153E point mutation in the Nudix motif affected the activity of the E. coli-produced enzyme. This point mutation (Q153E) completely blocked mRNA decapping in yeast based on mRNA analysis (Dunckley and Parker 1999) . Dcp2⌬Cp Q153E still interacts with Dcp1p as the mutant protein copurified with Flag Dcp1p over an anti-Flag column (data not shown). The resulting purified fraction, however, was unable to decap a cap-labeled MFA2 substrate (Fig. 2) . Therefore, similar to the yeast decapping activity, the Nudix motif in Dcp2⌬Cp is required for activity when the proteins are purified from E. coli.
Recombinant decapping activity prefers longer mRNA substrates and requires an exposed cap
The ability to produce active decapping enzyme in E. coli allowed us to examine various aspects of the decapping reaction. For example, the yeast-purified mRNA decapping activity was found to prefer substrates longer than 29 nucleotides (LaGrandeur and Parker 1998). Using the recombinant decapping activity we re-analyzed the size-dependence of the decapping reaction to determine if the requirement is an intrinsic property of the enzyme itself or a feature conveyed by other yeast proteins that copurify. As shown in Figure 3 the decapping activity is maximal with longer mRNA substrates (>60% of the 99-and 343-nucleotide-long substrate was decapped in 30Ј reaction) and is markedly less with shorter substrates (up to 6% of the 20-and 29-nucleotide-long substrate was decapped) and very small amounts of activity were detected with cap analog substrates (7meGpppG) (1% of the substrate was decapped). Therefore, the requirement for longer, capped mRNA substrates is an inherent requirement of the Dcp1p/ Dcp2p decapping enzyme.
There are two possible explanations for why a longer RNA substrate is preferred by the decapping enzyme. First, it could be that the enzyme contains an RNA-binding site separate from the active site for decapping and a longer substrate can more easily interact with both sites. Alternatively, it could be that the 3Ј end of the RNA is required for binding or catalysis, and a longer RNA substrate allows enough flexibility in the substrate for both ends to interact with the enzyme simultaneously.
Two experiments were done to examine the role of the 3Ј end in decapping. First, a 26-base DNA oligonucleotide with a 3Ј methyl group was ligated onto the 3Ј end of the mRNA, thereby replacing the normal RNA 3Ј end with DNA sequences. The substrate with a DNA 3Ј end was decapped as efficiently as an mRNA with a normal RNA 3Ј end (data not shown). In a second experiment, the requirement for different portions of the substrate was tested by the addition of DNA oligonucleotides complementary to the 25 nucleotides at the 5Ј end of the substrate, 26 nucleotides in the middle, or the 30 nucleotides at the 3Ј end of the substrate. Only the oligonucleotide annealed at the 5Ј end of the cap-labeled MFA2 substrate caused a significant decrease in decapping activity with the average inhibition by the 5Ј oligo being fivefold (Fig. 4) . This argues that sequestration of the 5Ј end of the mRNA can inhibit decapping, and raises the possibility that the decapping enzyme must interact with nucleotides near the 5Ј end. We interpret these experiments to indicate that the 3Ј end is not required for efficient decapping and therefore that the length-dependence is likely to represent an additional RNA-binding site on the decapping enzyme.
The Edc proteins enhance the recombinant decapping activity
The ability to produce recombinant decapping enzyme allows for analysis of the activity of other proteins implicated from yeast genetic screens for their ability to alter the decapping activity directly. Two small proteins known to en-FIGURE 2. Decapping activity requires a normal Nudix motif in Dcp2⌬Cp. Decapping assays analyzed the activity of purified protein fractions where Dcp2⌬Cp is wild type or has the E153Q mutation. Dcp1p is present and wild type in all these protein preparations. Decapping reactions were carried out with 1 fmole MFA2 substrate in a 10-µL reaction and ∼ 225 ng of total protein in the purified fractions. Products were separated by PEI cellulose TLC. (−) Reaction with no enzyme present.
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www.rnajournal.org hance decapping are Edc1p and Edc2p. These proteins were first identified as high copy suppressors of dcp1 and dcp2 point mutations (Dunckley et al. 2001 ). In addition, Edc1p and Edc2p purified from E. coli bind RNA, stimulate the activity of decapping enzyme purified from yeast, but do not show decapping activity themselves (Schwartz et al. 2003) . Given this, we used the recombinant Dcp1/ Dcp2⌬Cp decapping enzyme to determine if Edc1p and Edc2p act directly on the decapping enzyme.
To test the ability of Edc1p and Edc2p to stimulate decapping activity directly, the recombinant Edc1 and Edc2 proteins were added to decapping reactions with the recombinant Dcp1p/Dcp2⌬Cp. It should be noted that in these experiments we significantly reduced the amount of decapping enzyme present in the reactions compared with the earlier experiments to allow any stimulation to be more easily observed. An important result is that both Edc1p and Edc2p were independently able to directly stimulate the Dcp1p/ Dcp2⌬Cp decapping activity (Fig. 5) . The recombinant Edc1 protein increases the decapping of a 99-nucleotide-long RNA substrate by an average of 18-fold. Edc2 protein increases the decapping of a 99-nucleotide-long substrate by, on average, 32-fold. We interpret these results to indicate that Edc1p and Edc2p can activate decapping of the Dcp1p/Dcp2⌬Cp enzyme directly and without the requirement for any additional yeast proteins.
Dcp2⌬Cp contains intrinsic decapping activity
In the course of this work, the human Dcp2p was isolated and shown to be sufficient for decapping activity when produced in E. coli (Wang et al. 2002) . Furthermore, more recent data indicate that the use of manganese in the decapping reaction significantly increases the decapping activity of human Dcp2 (C. Piccirillo and M. Kiledjian, in prep.) . Given this, we examined the activity of the yeast Dcp1p, Dcp2⌬Cp, and the Dcp1p/Dcp2⌬Cp complex, formed by mixing individually purified Dcp1p and Dcp2⌬Cp, with Mg 2+ or Mg 2+ and Mn 2+ as cofactors using the buffer conditions where human Dcp2p gave activity. An important result was that Dcp2⌬Cp was clearly active in the presence of Mn 2+ (Fig. 6A, lane 7) . Consistent with Dcp2⌬Cp being capable of decapping, low level of decapping can be seen in the presence of Mg 2+ under these biochemical conditions. These results suggest that yeast Dcp2⌬Cp has intrinsic decapping activity. This conclusion was verified by an in-gel assay where Dcp2⌬Cp was resolved on an SDS-polyacrylamide gel containing cap-labeled RNA. The proteins were renatured as described in Materials and Methods and tested for decapping activity in the standard decapping buffer containing 2 mM Mn 2+ . As seen in Figure  6B , Dcp2⌬Cp was able to decap the gel-imbedded RNA as indicated by the zone of radioactive clearing around the protein. Further confirmation that the detected activity is a function of Dcp2⌬Cp is demonstrated by the lack of decapping activity (and clearing) by the Nudix mutant protein Dcp2⌬Cp Q153E . These data demonstrate that Dcp2⌬Cp contains decapping activity and is able to function independent of any other protein. However, as seen in Figures 1, 2 , and 6A, Dcp1p augments this activity.
DISCUSSION
Dcp1p and Dcp2p constitute the decapping holoenzyme
Several lines of evidence now suggest that the yeast decapping enzyme can be considered an enzyme complex of Dcp1p and Dcp2p. First, both of these proteins are absolutely required for decapping in vivo (Beelman et al. 1996; Dunckley and Parker 1999) . Second, Dcp1p and Dcp2p show numerous two-hybrid interactions and copurify in several genomic screens (Uetz et al. 2000; Gavin et al. 2002) . In addition, direct biochemical purification of either Dcp1p or Dcp2p expressed in yeast, or E. coli, copurifies the other partner (Dunckley and Parker 1999; Dunckley et al. 2001 ; data not shown). Similarly, recent results indicate that the mammalian homologs of Dcp1p and Dcp2p also coimmunoprecipitate, indicating that this interaction is conserved (Lykke-Andersen 2002 ).
An important issue is the specific roles of the yeast Dcp1p and Dcp2p in the process of mRNA decapping. Several observations indicate that Dcp2p is a catalytic subunit capable of cleaving the pyrophosphate cap linkage. This was first suggested by the Nudix motif in Dcp2p, which is required for decapping function, and constitutes a specific protein structure capable of cleaving different substrates of the class XpppY, producing Xpp and pY (Bessman et al. 1996) . More importantly, we have now demonstrated that under specific biochemical conditions, yDcp2p is capable of decapping an mRNA (Fig. 6A ). In addition, yDcp2p can be renatured in an SDS gel to yield decapping activity (Fig.  6B) . These results are consistent with work on the hDcp2p, which is sufficient for decapping activity by itself (Wang et al. 2002) . Because the Nudix motif is required for decapping in vivo and in vitro, the simplest interpretation is that the Dcp2p catalyzed decapping reaction is the major catalytic event in decapping.
The conclusion that Dcp2p can catalyze the mRNA decapping alone raises the question of how does Dcp1p function in mRNA decapping. Two observations suggest that Dcp1p enhances the activity of Dcp2p. First, Dcp1p is required for all decapping in vivo (Beelman et al. 1996) . This indicates that Dcp2p cannot function without Dcp1p in vivo. Second, under conditions where Dcp2p is not sufficient for decapping in vitro, the Dcp1p/Dcp2p complex shows robust decapping activity (Fig. 1) . Moreover, as this activity is dependent on the Nudix motif in Dcp2p (Fig. 2) , we interpret this reaction to be Dcp2p-catalyzed.
In addition to enhancing Dcp2p activity, several pieces of evidence suggest that Dcp1p may also have a catalytic activity. First, decapping activity colocalizes with Dcp1p renatured in gels (LaGrandeur and Parker 1998). Second, separation of Dcp1p and Dcp2p by high salt washes yielded preparations of Dcp1p with decapping activity and no detectable Dcp2p (Dunckley et al. 2001) . However, neither experiment can rule out the possibility that an undetected fragment of Dcp2p is present and responsible for the observed decapping activity. In addition, recombinant Dcp1p has been reported to have decapping activity (Vilela et al. 2000) . However, we have been unable to obtain active recombinant Dcp1p under a variety of conditions ( Fig. 1 ; data not shown). Given these results, and the clear decapping activity of Dcp2p, we cannot rule out the possibility that the Dcp1p/Dcp2p complex contains two different decapping proteins.
The possibility that the decapping complex may contain two catalytic subunits is intriguing because other enzymes involved in eukaryotic mRNA decay exist in complexes of multiple proteins with similar enzymatic activities. The most dramatic example of this phenomenon is the exosome, which contains 10 different potential 3Ј to 5Ј exonucleases (Mitchell et al. 1997; Allmang et al. 1999 ). In addition, in the major yeast deadenylase complex, consisting of Ccr4p, Pop2p, and Not1p-Not5p, both Ccr4p and 
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Pop2p contain exonuclease motifs. In this case, Ccr4p, and perhaps Pop2p, can function as an mRNA deadenylase in vitro (Daugeron et al. 2001; Tucker et al. 2001 Tucker et al. , 2002 Chen et al. 2002) . These observations raise the question of why eukaryotic mRNA decay enzymes are clustered in these complexes. One possibility is that the association of nucleases with similar activity allows for the control of substrate specificity. Specifically, these complexes may allow the cell to limit multiple nucleases simultaneously from acting on inappropriate substrates as well as coordinate their activity with correct substrates.
Modulation of decapping activity
One of the interesting properties of the Dcp1/Dcp2p decapping enzyme is that is shows greater activity on longer mRNA substrates. This was first reported with the enzyme purified from yeast (LaGrandeur and Parker 1998) and has now been extended to recombinantly produced enzyme (Fig. 4) . This indicates the length preference is a property of the enzyme and cannot be attributed to any copurifying proteins. Consistent with this view, the recombinant human Dcp2p decapping activity also prefers longer substrates (Wang et al. 2002) . The preference for a longer substrate implies that the Dcp2p also contains a site for binding RNA distinct from the active site. By filling this site, the activity of decapping would be enhanced, either by more efficient interaction of the substrate and the enzyme, or by inducing conformational changes that activate the decapping enzyme. Such a mechanism might be biologically relevant by dictating a requirement for substantial exposed RNA, which might correspond to an mRNP state targeted for decay, before decapping.
Edc1p and Edc2p also activate decapping (Dunckley et al. 2001; Schwartz et al. 2003) . We have now shown that this effect is directly on the decapping enzyme and can be reconstituted with recombinant proteins (Fig. 5) . In principle, the Edc proteins could enhance decapping by one of two likely mechanisms. First, because Edc1 and Edc2p are RNAbinding proteins, the Edc proteins might stimulate decapping by binding both the mRNA substrate and the Dcp1p/ Dcp2p decapping enzyme, thereby enhancing the interaction of the enzyme with the substrate and/or the catalytic rate of the enzyme. Alternatively, and not mutually exclusive, Edc1p or Edc2p could act as allosteric activators of the decapping enzyme independent of any Edc-RNA interaction. In either case, the production of recombinant proteins should allow the clear resolution of the mechanisms and control by these proteins and other activators or inhibitors of decapping.
MATERIALS AND METHODS
Construction of Flag-Dcp1p and His 6 Dcp2p overexpression vector
The plasmid expressing a His-Dcp1p in E. coli (pRP785) was constructed by amplifying Dcp1p with PCR primers oRP247 (5Ј-CAGACGGGATCCTCAGCAAAAGAATCTTTTGG-3Ј) and oRP248 (5Ј-CAGAGAGGCGCCATGACCGAGCAAC-3Ј) and inserting the NarI/BamHI cut fragment into the NarI/BamHI sites of pPROEX-1 (GIBCO/BRL).
The plasmid for overproducing both DCP1 and DCP2 in E. coli, pRP 1071, was constructed as follows. His 6 DCP2⌬C gene was created by PCR amplifying DCP2 from pRP 925 with the oligonucleotides oRP1126 (CAGAGAGAGCTCGATGTCACTGCCGC TACGACAC) and oRP 1127 (CAGACGGGATCCTCACTCTTG GCTCGAGGGTACCTG) and inserting the SacI/BamHI-cut PCR product into the SacI/BamHI sites of pPROEX-1 (GIBCO-BRL). FLAG DCP1 gene was obtained from a BglII and BamHI digestion of a pET 5a vector with FLAG DCP1 inserted into the NdeIBamHI sites (a gift from John McCarthy). The BglII and BamHI fragment with FLAG DCP1 was ligated into the BamHI site of pPROEX-1 vector to create pRP1080.
The Q153E mutation was introduced into DCP2 by using the QuikChange site-directed mutagenesis kit (Stratagene) and the oligonucleotides GCATTAGAGAAGTGAAAGAACAAATTG GTTTCGATTTGACGG (oRP 1131) and CCGTCAAATCGAAAC CAATTTGTTCTTTCACTTCTCTAATGC (oRP 1132).
Expression and purification of Flag-Dcp1p and His 6 Dcp2⌬Cp
Expression of both genes is controlled from the pPROEX-1 lacZ promoter in DH5␣ cells. Cells containing pRP1071 or pRP1080 are grown in 750 mL of LB media containing ampicillin at 37°C and cells were induced once the OD 600 nm reached 0.4-0.6 with 0.6 mM IPTG (isopropyl-b-D-thiogalactopyranoside) for 3 h at 37°C. Induced cells were collected by centrifugation at 5000 rpm for 15 min at 4°C, washed with water, recollected, and frozen.
Frozen cell pellets were thawed on ice, resuspended in ∼ 4 mL of sonication buffer (10 mM Tris-HCl, pH 7.5, 1 M KCl, 2mM magnesium acetate, 1 mM DTT, 1 mg/mL lysozyme) in the presence of Mini complete-EDTA free protease inhibitors (La Roche), incubated for 30 min on ice, then sonicated for four, 15-sec rounds, with 1 min on ice incubation between rounds. The cell debris was pelleted by centrifugation in a tabletop centrifuge at 11K for 10 min. The supernatant was removed and used in the subsequent steps.
The clarified cell lysate was diluted with no salt sonication buffer to a final concentration of 100 mM KCl, it was then bound to anti-Flag affinity resin by mixing 1 h at 4°C. Approximately 1 mL of resin was used for a 750 mL culture of cells grown, induced, and lysed. The resin was spun down at 2000 rpm for 5 min at 4°C; the supernatant was saved as the flow-thru, the resin was poured into a solid support column, and washed with 50 column volumes of wash buffer (10 mM Tris-HCl, pH 7.5, 100 mM KCl, 2mM magnesium acetate, 1 mM DTT). The column was then washed with 10 column volumes of high-salt wash buffer (same as wash buffer but with 700 mM KCl) followed by washing with 10 column volumes of wash buffer. Proteins were eluted with wash buffer containing 200 µg/mL FLAG peptide and dialyzed overnight at 4°C into 50% glycerol, 50 mM Tris-HCl, pH 7.5, 1 mM DTT, and stored at −20°C. Purified protein fractions were analyzed by standard SDS polyacrylamide gel electrophoresis methods on 12% polyacrylamide gels.
Decapping reactions and analysis on TLC plates
Cap-labeled MFA2 mRNA substrates of various nucleotide lengths were prepared as previously described (LaGrandeur and Parker 1998) . Except the short substrates, 29-, 20-, and 1-(cap analog m 7 GpppG) nucleotides-long were generated by capping a 99-nucleotide-long MFA2 transcript, annealing an oligonucleotide, cleaving the RNA with RNase H for 1 h at 30°C, treating the DNA with DNase I, RNase free (La Roche), and purifying the RNAs by polyacrylamide electrophoresis. The oligonucleotide used for generating the 29-nucleotide MFA2 was the oligonucleotide GATC GGTTGCATTAAGGTTGGTA (oRP 1136), for the 20-nucleotide and cap analog MFA2 mRNA substrates the oligonucleotide was GCATTAAGGTTGGTAGTTATTGTT (oRP 1135). Cap-labeled pcP-G 16 RNA corresponding to the pcDNA3 polylinker with a G-track of 16 guanosines was prepared as previously described (Wang and Kiledjian 2001) .
Decapping reactions were carried out as previously described (LaGranduer and Parker 1998) except the reaction buffer consisted of 50 mM Tris-HCl, pH 7.5, 5 mM MgCl 2 , 50 mM NH 4 Cl, and 1 mM DTT and each reaction contained ∼ 1 fmole of the indicated MFA2 substrate. Reactions were stopped by mixing with 1 µL of 0.5 M EDTA to the reaction aliquot and placing on ice. Products were separated on a PEI Cellulose thin layer chromatography plate (Selecto) in 0.45 (NH 4 ) 2 SO 4 and detected with a Molecular Dynamics PhosphorImager. For Figure 6 , the decapping reaction buffer consisted of 10 mM Tris-Hcl (pH7.5), 100 mM K-Ac, 2 mM Mg-Ac, 2 mM DTT, 0.1 mM Spermine, and each reaction contained 0.5 ✕ 10 6 cpm of cap labeled pcP-G 16 RNA. Five microliters of the 20 µL reaction products was separated on a PEI Cellulose thin layer chromatography plate (Sigma) in 0.75 LiCl and detected as above.
Decapping reactions with a DNA oligonucleotide inhibitor were performed as described above with the MFA2 mRNA substrate that is 99 nucleotides long and ∼ 0.6 ngrams of purified decapping protein. The oligonucleotide used to inhibit the 5Ј end was GT TGTATGAAGATGATAGCTCGCCC (oRP 1137). The oligonucleotide used to inhibit the 3Ј end was CTTTTCAGAGGATT TATCCTTCTGAGTGGC (oRP 1138). The oligonucleotide used to inhibit the middle, complements ∼ 45 nucleotides from the 5Ј end, GTGTGGAAGCAGTGGTGATCGGTTGC (oRP 1130). In each case, the oligonucleotide was used at a variety of concentrations with the results shown in the figure at a concentration of 6 pmoles.
Purification and characterization for the Edc proteins used here are described in Schwartz et al. (2003) . Reactions with Edc1p and Edc2p were performed as described above with ∼ 0.24 ngrams of decapping enzyme; reactions without either Edc protein added had an equal amount of BSA added in the same buffer as the Edc proteins were stored in (20 mM HEPES, pH 7.5 and 50 mM KCl) to keep the amount of protein the same in all reactions.
In-gel decapping assays
In-gel decapping assays were carried out with 3 µg each of Dcp2⌬Cp or Dcp2⌬CpQ153E resolved on either a standard 15% SDS-PAGE gel or a 15% SDS-PAGE gel containing cap-labeled pcP-G 16 RNA (1 ✕ 10 6 cpm) immobilized in the running gel. The two SDS-PAGE gels were subjected to electrophoresis under identical conditions and proteins in the unlabeled gel were visualized Analysis of recombinant yeast decapping enzyme www.rnajournal.org by Coomassie blue staining. Proteins in the cap-labeled RNAcontaining gel were renatured at 4°C as described in LaGrandeur and Parker (1998) and assayed for decapping activity at 30°C in the following buffer: (10 mM Tris-Hcl (pH7.5), 100 mM K-Ac, 2 mM Mg-Ac, 2 mM MnCl 2 , 2 mM DTT, 0.1 mM Spermine). The gel was subsequently dried and exposed to Kodak X-ray film.
